{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > PI3K/Akt/mTOR > PictilisibCAS：957054-30-7
Molecular Formula：C23H27N7O3S2
Molecular Weight：513.64
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：Off-white to yellow Solid
Qty：
Size：
| CAS | 957054-30-7 |
| Name | Pictilisib |
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.64 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥98% |
| Appearance | Off-white to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 1312995-182-4 |
| MDL | MFCD11616196 |
| SMILES | CS(N1CCN(CC2=CC3=C(C(N4CCOCC4)=NC(C5=CC=CC6=C5C=NN6)=N3)S2)CC1)(=O)=O |
| Target Point | PI3K |
| Passage | PI3K/Akt/mTOR |
| Background | GDC-0941 is a potent PI3Kα/δ inhibitor. |
| Biological Activity | GDC-0941 是有效的 PI3Kα/δ 抑制剂, IC50为 3 nM; 对110β (11倍) 和 p110γ (25倍) 具有适度的选择性[1-7]。 |
| IC50 | p110α:3nM (IC50) p110α-H1047R:3nM (IC50) p110α-E545K:3nM (IC50) p110δ:3nM (IC50) p110β:33nM (IC50) p110γ:75nM (IC50)mTOR:0.58μM (Ki) DNA-PK:1.23μM (IC50) [1-7] |
| Data Literature Source | [1]. Wallin JJ， et al. GDC-0941， a novel class I selective PI3K inhibitor， enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.Clin Cancer Res. 2012 Jul 15; 18 (14) :3901-11. Epub 2012 May 14. [2]. Wullschleger S， et al. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.Anticancer Res. 2012 Feb; 32 (2) :415-20. [3]. Zou ZQ， et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.Mol Med Report. 2012 Feb; 5 (2) :503-8. [4]. Burrows N， et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.J Clin Endocrinol Metab. 2011 Dec; 96 (12) :E1934-43. Epub 2011 Oct [5]. Folkes AJ， et al. The identification of 2- (1H-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3，2-d]pyrimidine (GDC-0941) as a potent， selective， orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25; 51 (18) :5522-32. [6]. Ni J， et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May; 2 (5) :425-33. [7]. Cheng H， et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014 Jan 1; 74 (1) :15-23. |
| Unit | Bottle |
| Specification | 10mg 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
